NASHUA, NH, 19 July 2017 – iCAD, Inc. (Nasdaq: ICAD), an industry-leading provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer, today announced that results of a matched-pair cohort study of 369 early-stage non-melanoma skin cancer (NMSC) patients treated with the Company’s Xoft® Axxent® Electronic Brachytherapy (eBx®) System® or Mohs micrographic surgery showed that rates of recurrence of cancer were virtually identical. Mohs micrographic surgery is accepted as the most effective technique for removing basal cell carcinoma and squamous cell carcinoma, the two most common skin cancers. The study results were published online in the peer-reviewed Journal of Contemporary Brachytherapy.

“In recent years, we have seen substantial clinical evidence indicating that electronic brachytherapy offers comparable results to Mohs surgery in appropriately selected early-stage non-melanoma skin cancer patients,” said Rakesh Patel, MD, lead investigator of the study, Radiation Oncologist and Medical Director, Department of Radiation Oncology, Good Samaritan Hospital, Los Gatos, CA. “These data provide an entirely new level of clinical research confirming that treatment with eBx can help patients achieve similar low rates of recurrence with excellent cosmetic outcomes compared to Mohs surgery.”

The study compared clinical outcomes of patients treated with eBx and Mohs surgery at different treatment centers. In the population of 369 patients, a total of 188 were treated with eBx and 181 with Mohs surgery. Data reflected treatment of 416 lesions (208 in the eBx group and 208 in the Mohs surgery group), including 226 basal cell carcinomas and 190 squamous cell carcinomas. At a mean follow up of 3.4 years, 99.5% of eBx patients and 100% of Mohs surgery patients remained recurrence free. Statistics provided by the American College of Mohs Surgery state that Mohs surgery has a success rate “up to 99 percent.” Overall incidence of toxicity was similar in both treatment groups. In addition, physician-rated cosmetic outcomes were either “excellent” or “good” in 97.6% of eBx-treated lesions and 95.7% of Mohs surgery-treated lesions.
“For appropriately selected NMSC patients, the Xoft System delivers a targeted therapeutic dose of radiation directly to the cancerous site in a painless, non-invasive procedure,” said Ken Ferry, CEO of iCAD. “The results of this landmark study can help more patients choose treatment with eBx with the confidence that recurrence rates are clinically shown to be similar to those observed with Mohs surgery, which has been considered the standard of care for early-stage NMSC for decades.”

Rad Oncology Homepage